Trial · NCT05653349
Registered outcomes26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 26 of 26
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | PK parameter: AUCtau | After first dose (pre-dose, 2, 168, 336 and 504 hours post dose) and after last dose (pre-dose, 2, 336, 672, 1344, 2016, 3360 hours post dose) | Area under the curve calculated to the end of a dosing interval (tau) |
| Secondary | PK parameters: Cmax | After first dose (pre-dose, 2, 168, 336 and 504 hours post dose) and after last dose (pre-dose, 2, 336, 672, 1344, 2016, 3360 hours post dose) | Maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration |
| Secondary | PK parameters: Tmax | After first dose (pre-dose, 2, 168, 336 and 504 hours post dose) and after last dose (pre-dose, 2, 336, 672, 1344, 2016, 3360 hours post dose) | Time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration |
| Secondary | PK parameters: Accumulation ratio Racc | After last dose (pre-dose, 2, 336, 672, 1344, 2016, 3360 hours post dose) | Accumulation ratio calculated using AUC values obtained between the last and first dose |
| Secondary | Incidence of anti-ianalumab antibodies in serum (ADA assay) over time | Up to Week 33 | Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants assess the immunogenicity of ianalumab |
| Secondary | Titer of anti-ianalumab antibodies in serum (ADA assay) over time | Up to Week 33 | Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants assess the immunogenicity of ianalumab |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05653349/registered?page=2